直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 117393
著者
Sako, Masahiro Tokushima University|Tokushima Prefectural Central Hospital
軒原, 浩 Tokushima University
Kondo, Kensuke Tokushima University|Tokushima Prefectural Central Hospital
Yabuki, Yohei Tokushima University
阿部, あかね Tokushima University
米田, 浩人 Tokushima University
大塚, 憲司 Tokushima University
キーワード
interstitial pneumonia
pembrolizumab
pulmonary pleomorphic carcinoma
資料タイプ
学術雑誌論文
抄録
Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune-related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients.
掲載誌名
Thoracic Cancer
ISSN
17597714
出版者
China Lung Oncology Group|John Wiley & Sons Australia
13
1
開始ページ
129
終了ページ
132
発行日
2021-12-03
権利情報
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
病院
医学系